Cellectar Biosciences Inc... (CLRB)

NASDAQ: CLRB · Real-Time Price · USD

0.26

0.01 (3.34%)

At close: May 01, 2025, 3:59 PM

0.28

5.49%

Pre-market: May 02, 2025, 07:00 AM EDT

3.34% (1D)

Bid	0.27
Market Cap	12.17M
Revenue (ttm)	n/a
Net Income (ttm)	-39.52M
EPS (ttm)	-1.4
PE Ratio (ttm)	-0.19
Forward PE	-0.36
Analyst	Buy

Ask	0.28
Volume	335,321
Avg. Volume (20D)	1,131,524
Open	0.26
Previous Close	0.25
Day's Range	0.25 - 0.27
52-Week Range	0.22 - 3.51
Beta	0.67

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 10, 2005

Employees 11

Stock Exchange NASDAQ

Ticker Symbol CLRB

Website https://www.cellectar.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 10506.06% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

-13.54%

CLRB stock has given up its prior gain. Cellectar ... Unlock content with Pro Subscription

1 day ago New

-13.54%

Cellectar Biosciences shares are trading higher after the company announced a plan to explore strategic alternatives.

News

2 weeks ago · zacks.com

4 Medical Product Stocks to Buy From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from ...

1 month ago · zacks.com

Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?

Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and ...